Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
- DOI
- 10.1016/s0140-6736(15)00239-1
- Published
- 2015 Nov 21
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-15-00239-1,
title = {Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.},
author = {Trimble CL and Morrow MP and Kraynyak KA and Shen X and Dallas M and Yan J and Edwards L and Parker RL and Denny L and Giffear M and Brown AS and Marcozzi-Pierce K and Shah D and Slager AM and Sylvester AJ and Khan A and Broderick KE and Juba RJ and Herring TA and Boyer J and Lee J and Sardesai NY and Weiner DB and Bagarazzi ML},
year = {2015},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(15)00239-1},
url = {https://doi.org/10.1016/s0140-6736(15)00239-1}
}RIS
TY - JOUR TI - Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. AU - Trimble CL AU - Morrow MP AU - Kraynyak KA AU - Shen X AU - Dallas M AU - Yan J AU - Edwards L AU - Parker RL AU - Denny L AU - Giffear M AU - Brown AS AU - Marcozzi-Pierce K AU - Shah D AU - Slager AM AU - Sylvester AJ AU - Khan A AU - Broderick KE AU - Juba RJ AU - Herring TA AU - Boyer J AU - Lee J AU - Sardesai NY AU - Weiner DB AU - Bagarazzi ML PY - 2015 JO - Lancet (London, England) DO - 10.1016/s0140-6736(15)00239-1 UR - https://doi.org/10.1016/s0140-6736(15)00239-1 ER -
APA
CL, T., MP, M., KA, K., X, S., M, D., J, Y., L, E., RL, P., L, D., M, G., AS, B., K, M., D, S., AM, S., AJ, S., A, K., KE, B., RJ, J., TA, H., J, B., J, L., NY, S., DB, W., & ML, B. (2015). Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(15)00239-1
Source records
- pubmed · retrieved 2026-09-26T13:33:47.663Z
- europe-pmc · retrieved 2026-09-26T13:33:47.655Z